EIF2AK2 expression based on
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Comparison | Statistical significance |
Normal-vs-Primary | 1.40700007200678E-10 |
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Stage1 |
3.79050000054448E-07 |
Normal-vs-Stage2 |
2.617900E-03 |
Normal-vs-Stage3 |
N/A |
Normal-vs-Stage4 |
1.516180E-02 |
Stage1-vs-Stage2 |
2.867400E-01 |
Stage1-vs-Stage3 |
N/A |
Stage1-vs-Stage4 |
8.280400E-01 |
Stage2-vs-Stage3 |
N/A |
Stage2-vs-Stage4 |
5.866600E-01 |
Stage3-vs-Stage4 |
N/A |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Caucasian |
3.47149997637075E-09 |
Normal-vs-AfricanAmerican |
3.667600E-01 |
Normal-vs-Asian |
6.891900E-02 |
Caucasian-vs-AfricanAmerican |
3.024800E-01 |
Caucasian-vs-Asian |
7.850000E-01 |
AfricanAmerican-vs-Asian |
2.533200E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Male |
6.02189999999725E-05 |
Normal-vs-Female |
8.79809999965175E-07 |
Male-vs-Female |
1.508380E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Patient BMI information is not available for 1 sample.
Descriptions |
Normal weight |
BMI greater than equal to 18.5 and BMI less than 25 |
Extereme weight |
BMI greater than equal to 25 and BMI less than 30 |
Obese |
BMI greater than equal to 30 and BMI less than 40 |
Extreme Obese |
BMI greater than 40 |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Normal_Weight |
3.298000E-03 |
Normal-vs-Extreme_Weight |
6.49619999999462E-05 |
Normal-vs-Obese |
4.636900E-03 |
Normal-vs-Extreme_Obese |
N/A |
Normal_Weight-vs-Extreme_Weight |
7.412600E-01 |
Normal_Weight-vs-Obese |
8.440200E-01 |
Normal_Weight-vs-Extreme_Obese |
N/A |
Extreme_Weight-vs-Obese |
5.816400E-01 |
Extreme_Weight-vs-Extreme_Obese |
N/A |
Obese-vs-Extreme_Obese |
N/A |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Age(21-40Yrs) |
8.739600E-02 |
Normal-vs-Age(41-60Yrs) |
3.157800E-04 |
Normal-vs-Age(61-80Yrs) |
9.42610000054245E-07 |
Normal-vs-Age(81-100Yrs) |
5.325600E-01 |
Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.538700E-03 |
Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.272300E-02 |
Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.111960E-01 |
Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.232400E-01 |
Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.378200E-01 |
Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.007000E-01 |
|
|
CHOL : Cholangiocarcinoma
Subtype descriptions |
Grade 1 | Well differentiated (low grade) |
Grade 2 | Moderately differentiated (intermediate grade) |
Grade 3 | Poorly differentiated (high grade) |
Grade 4 | Undifferentiated (high grade) |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Grade 1 |
N/A |
Normal-vs-Grade 2 |
2.038600E-01 |
Normal-vs-Grade 3 |
9.637600E-02 |
Normal-vs-Grade 4 |
1.000000E+00 |
Grade 1-vs-Grade 2 |
N/A |
Grade 1-vs-Grade 3 |
N/A |
Grade 1-vs-Grade 4 |
N/A |
Grade 2-vs-Grade 3 |
4.774600E-01 |
Grade 2-vs-Grade 4 |
2.038600E-01 |
Grade 3-vs-Grade 4 |
9.637600E-02 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 5 samples.
pathologic_N descriptions |
N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-N0 |
1.53689999948803E-07 |
Normal-vs-N1 |
2.634300E-02 |
N0-vs-N1 |
5.099000E-01 |
|
|